5cck: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
==Crystal structure of Human anti-HIV-1 broadly neutralizing antibody 3BC315 Fab== | ==Crystal structure of Human anti-HIV-1 broadly neutralizing antibody 3BC315 Fab== | ||
<StructureSection load='5cck' size='340' side='right' caption='[[5cck]], [[Resolution|resolution]] 1.95Å' scene=''> | <StructureSection load='5cck' size='340' side='right' caption='[[5cck]], [[Resolution|resolution]] 1.95Å' scene=''> | ||
| Line 5: | Line 6: | ||
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=CXS:3-CYCLOHEXYL-1-PROPYLSULFONIC+ACID'>CXS</scene></td></tr> | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=CXS:3-CYCLOHEXYL-1-PROPYLSULFONIC+ACID'>CXS</scene></td></tr> | ||
<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[5awn|5awn]]</td></tr> | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[5awn|5awn]]</td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5cck FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5cck OCA], [http://pdbe.org/5cck PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5cck RCSB], [http://www.ebi.ac.uk/pdbsum/5cck PDBsum]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5cck FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5cck OCA], [http://pdbe.org/5cck PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5cck RCSB], [http://www.ebi.ac.uk/pdbsum/5cck PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5cck ProSAT]</span></td></tr> | ||
</table> | </table> | ||
<div style="background-color:#fffaf0;"> | <div style="background-color:#fffaf0;"> | ||
| Line 16: | Line 17: | ||
</div> | </div> | ||
<div class="pdbe-citations 5cck" style="background-color:#fffaf0;"></div> | <div class="pdbe-citations 5cck" style="background-color:#fffaf0;"></div> | ||
==See Also== | |||
*[[3D structures of antibody|3D structures of antibody]] | |||
== References == | == References == | ||
<references/> | <references/> | ||
Revision as of 09:33, 6 October 2017
Crystal structure of Human anti-HIV-1 broadly neutralizing antibody 3BC315 FabCrystal structure of Human anti-HIV-1 broadly neutralizing antibody 3BC315 Fab
Structural highlights
Publication Abstract from PubMedThe recent identification of three broadly neutralizing antibodies (bnAbs) against gp120-gp41 interface epitopes has expanded the targetable surface on the HIV-1 envelope glycoprotein (Env) trimer. By using biochemical, biophysical and computational methods, we map the previously unknown trimer epitopes of two related antibodies, 3BC315 and 3BC176. A cryo-EM reconstruction of a soluble Env trimer bound to 3BC315 Fab at 9.3 A resolution reveals that the antibody binds between two gp41 protomers, and neutralizes the virus by accelerating trimer decay. In contrast, bnAb 35O22 binding to a partially overlapping quaternary epitope at the gp120-gp41 interface does not induce decay. A conserved gp41-proximal glycan at N88 was also shown to play a role in the binding kinetics of 3BC176 and 3BC315. Finally, our data suggest that the dynamic structure of the Env trimer influences exposure of bnAb epitopes. Antibodies to a conformational epitope on gp41 neutralize HIV-1 by destabilizing the Env spike.,Lee JH, Leaman DP, Kim AS, Torrents de la Pena A, Sliepen K, Yasmeen A, Derking R, Ramos A, de Taeye SW, Ozorowski G, Klein F, Burton DR, Nussenzweig MC, Poignard P, Moore JP, Klasse PJ, Sanders RW, Zwick MB, Wilson IA, Ward AB Nat Commun. 2015 Sep 25;6:8167. doi: 10.1038/ncomms9167. PMID:26404402[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
| ||||||||||||||||||